The global market for 2, 4-dichlorobenzyl alcohol is witnessing a spurting rise recently, mainly due to the coronavirus outbreak. Rising usages of DCBA substrates in the treatment or prevention of viral infections caused by SARS-associated coronavirus acts as a key driving force for the market growth. Moreover, growth in the rapidly growing end-use industries of DCBA, such as pharmaceutical, agriculture, cosmetics personal care, and general industries accelerates the market growth.
According to Market Research Future (MRFR), the global 2, 4-dichlorobenzyl alcohol market is poised to witness significant growth by 2023, registering an impressive CAGR during the forecast period (2017–2023). Increasing incidences of chronic disease push the consumption of DCBA in the pharmaceutical industry to develop breakthrough medicines. Also, advances in active pharmaceutical ingredients (API) manufacturing technology, alongside the growing urbanization worldwide, foster the growth of the market.
Additionally, the increasing usages of DCBA materials in agricultural activities led by the rising demand for quality crop production are predicted to drive market growth during the forecast period. Moreover, increasing awareness among farmers about the benefits of insecticide on crop yield is estimated to fuel the growth of the market. Also, the massive absorption of DCBA by the prominent end-use industries would help the market to grow at a steady pace.
Sample link - https://www.marketresearchfuture.com/sample_request/4348
On the other hand, stringent regulation implemented by REACH and EPA to limit DCBA content in cosmetics personal care is expected to slightly hamper the growth of the market, especially in Europe and North American regions. Nevertheless, the awareness of personal hygiene increasing due to the COVID 19 pandemic would support the growth of the market, increasing the consumption of sanitation products.
2, 4-Dichlorobenzyl Alcohol Market - Segments
The report is segmented into three dynamics;
By Application : Insecticide, Preservative, Chemical Intermediate, and others.
By End Use Industry : Agriculture, Pharmaceutical, Cosmetics Personal Care, General Industry, and others.
By Regions : Europe, North America, APAC, and Rest-of-the-world.
Global 2, 4-Dichlorobenzyl Alcohol Market - Regional Analysis
North America dominates the global 2, 4-dichlorobenzyl alcohol market. The largest market share attributes to the strong base for the industrial sector and increasing applications of DCBA in rapidly growing end-use industries in the region. Besides, rising investments made in the development of medicines containing DCBA for the treatment or prevention of viral infections caused by SARS-associated coronavirus.
The US DCBA market leads the regional market, heading with the higher penetration of pharma industries in the country. The North American 2, 4-dichlorobenzyl alcohol market is expected to witness significant growth over the forecast period.
Europe stands second in the global 2, 4-dichlorobenzyl alcohol market. The market is majorly driven by developed end-use industries and rising expenditure on research and development. Moreover, factors such as innovations in medicines and increasing per capita healthcare expenditures foster regional market growth. European countries such as Russia, Germany, France, Italy, and the UK have emerged as a prominent consumer market for DCBA due to rising usages in pharmaceutical sectors.
The 2, 4-dichlorobenzyl alcohol market in the Asia Pacific region is emerging as a promising market. Factors such as the expansion in various end-use industries such as agriculture and cosmetics personal care and favorable regulatory framework for products containing DCBA drive the regional market growth. Besides, increasing consumer base, rising per capita incomes and the raw material advantage in the region fosters the regional DCBA market growth. The APAC DCBA market is estimated to grow at the highest CAGR during the review period.
Global 2, 4-Dichlorobenzyl Alcohol Market – Competitive Landscape
The DCBA market appears to be highly competitive due to the presence of several well-established players. The growth potential demonstrated by the market attracts several new entrants. The market competition is estimated to fierce during the anticipated period. Due to the low product differentiation and similarities, these players aim to develop their DCBA uniquely and minimize brand recall through effective marketing communications.
Access Complete Report @
https://www.marketresearchfuture.com/reports/2-4-dichlorobenzyl-alcohol-market-4348
Also, to gain a larger competitive share, players adopt strategic approaches such as mergers acquisitions, collaboration, expansion, and technology launch. To increase their foothold in the market, players offer products at much lower prices. To extend their geographical reach and maximize their profit shares, these players focus on increasing their market value.
Major Players
Players leading the global DCBA market include Reckitt Benckiser Healthcare International Ltd. (UK), BASF SE (Germany), Sigma-Aldrich Co. LLC (US), Santa Cruz Biotechnology, Inc. (US), EMKA-Chemie Gmbh Co. KG (Germany), Bioxera Pharma Private Limited (India), and Benzo Chem Industries Pvt. Ltd. (India), among others.
Industry/ Innovation/ Related News:
February 24, 2020 ---- BMC Research Notes (the UK), a research organization supporting all scientific and clinical disciplines, announced that one of its group of scientists presented findings of the study on Bactericidal activity of hexylresorcinol lozenges to fight oropharyngeal organisms associated with an acute sore throat. The team concluded that that hexylresorcinol lozenges offer rapid relief in organisms implicated in acute sore throat.
In a similar in vitro study, scientists reported that lozenges containing 0.6 mg amylmetacresol (AMC) and 1.2 mg 2,4-dichlorobenzyl alcohol show antibacterial activity against a similar range of oropharyngeal organisms associated with the acute sore throat. Acute sore throat is a common symptom in an upper respiratory tract infection (URTI) related to inflammation of the pharynx, tonsils, or nasopharynx.
The present invention indicates the use of formulations of DCBA and amylmetacresol in the treatment or prevention of Severe Acute Respiratory Syndrome (SARS), a viral respiratory illness caused by a novel coronavirus, termed as SARS-associated coronavirus (SARS-CoV). The pharmaceutical composition comprising 2,4-dichlorobenzyl alcohol and amylmetacresol can be used in the treatment prevention of viral infections caused by SARS-associated coronavirus.
